A new study has highlighted two new potential families of drug molecules that could open the door to new treatments for tuberculosis (TB). TB, caused by the bacterium Mycobacterium TB, is the second largest infectious killer globally after Covid-19 and causes 1.3 million deaths annually. … Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The headline news this week all concerns clinical trials for new drugs that could… Read More
News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. Read More
A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin. The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB. Read More
A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment. The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in… Read More
